RxDoctor Payments Data

Najwa Bahu Baugh, MD

Internal Medicine · Monterey, CANPI 1891893657

Payments from drug & device makers

$8,161in general payments, 2019–2025

Across 408 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Actelion Pharmaceuticals US, Inc.$554
  • Boehringer Ingelheim$457
  • AbbVie$269
  • Merck$247
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,93497%
  • Education$2273%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,161 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$162,133
Medicare patients
877
Services billed
2,091

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter566$480,578
OfevNintedanib Esylate25$234,507
Breztri AerosphereBudesonide/Glycopyr/Formoterol168$134,249
NucalaMepolizumab18$88,597
Spiriva RespimatTiotropium Bromide137$77,221
Breo ElliptaFluticasone/Vilanterol153$76,876
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr75$37,132
SymbicortBudesonide/Formoterol Fumarate114$30,419
Pirfenidone15$29,797
Incruse ElliptaUmeclidinium Bromide65$27,454
EliquisApixaban24$27,211
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$19,412
MicafunginMicafungin Sodium47$19,382
Spiriva HandihalerTiotropium Bromide20$15,786
Albuterol Sulfate HfaAlbuterol Sulfate519$15,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,043$725,959945 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$457$343,114208 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,382$164,669282 claims
PfizerEliquis$215$27,21124 claims
MerckDulera$247$4,15013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →